Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model

T Jake Liang; John L M Law; Thomas Pietschmann; Stuart C Ray; Jens Bukh; Rowena Bull; Raymond T Chung; D Lorne Tyrrell; Michael Houghton; Charles M Rice

doi:10.1093/cid/ciad336

Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model

T Jake Liang, John L M Law, Thomas Pietschmann, Stuart C Ray, Jens Bukh, Rowena Bull, Raymond T Chung, D Lorne Tyrrell, Michael Houghton, Charles M Rice

Department of Infectious Diseases

6 Citations (Scopus)

Abstract

For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of several viral genotypes with extensive virologic, serologic, and molecular characterizations should be the most appropriate approach. These inocula should first be tested in human volunteers in a step-wise manner to ensure safety, reproducibility, and curability prior to using them for testing the efficacy of candidate vaccines.

Original language	English
Journal	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume	77
Issue number	Suppl 3
Pages (from-to)	S257-S261
ISSN	1058-4838
DOIs	https://doi.org/10.1093/cid/ciad336
Publication status	Published - 14 Aug 2023

Keywords

Hepacivirus/genetics
Hepatitis C
Humans
Reproducibility of Results
treatment
vaccine development
acute hepatitis
risk-benefit analysis

Access to Document

10.1093/cid/ciad336

Cite this

Liang, T. J., Law, J. L. M., Pietschmann, T., Ray, S. C., Bukh, J., Bull, R., Chung, R. T., Tyrrell, D. L., Houghton, M., & Rice, C. M. (2023). Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 77(Suppl 3), S257-S261. https://doi.org/10.1093/cid/ciad336

Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model. / Liang, T Jake; Law, John L M; Pietschmann, Thomas et al.
In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 77, No. Suppl 3, 14.08.2023, p. S257-S261.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{375febd5cbc14d63b99372ac1ad8bfed,

title = "Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model",

abstract = "For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of several viral genotypes with extensive virologic, serologic, and molecular characterizations should be the most appropriate approach. These inocula should first be tested in human volunteers in a step-wise manner to ensure safety, reproducibility, and curability prior to using them for testing the efficacy of candidate vaccines.",

keywords = "Hepacivirus/genetics, Hepatitis C, Humans, Reproducibility of Results, treatment, vaccine development, acute hepatitis, risk-benefit analysis",

author = "Liang, \{T Jake\} and Law, \{John L M\} and Thomas Pietschmann and Ray, \{Stuart C\} and Jens Bukh and Rowena Bull and Chung, \{Raymond T\} and Tyrrell, \{D Lorne\} and Michael Houghton and Rice, \{Charles M\}",

note = "Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.",

year = "2023",

month = aug,

day = "14",

doi = "10.1093/cid/ciad336",

language = "English",

volume = "77",

pages = "S257--S261",

journal = "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "Suppl 3",

}

TY - JOUR

T1 - Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model

AU - Liang, T Jake

AU - Law, John L M

AU - Pietschmann, Thomas

AU - Ray, Stuart C

AU - Bukh, Jens

AU - Bull, Rowena

AU - Chung, Raymond T

AU - Tyrrell, D Lorne

AU - Houghton, Michael

AU - Rice, Charles M

N1 - Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.

PY - 2023/8/14

Y1 - 2023/8/14

N2 - For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of several viral genotypes with extensive virologic, serologic, and molecular characterizations should be the most appropriate approach. These inocula should first be tested in human volunteers in a step-wise manner to ensure safety, reproducibility, and curability prior to using them for testing the efficacy of candidate vaccines.

AB - For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of several viral genotypes with extensive virologic, serologic, and molecular characterizations should be the most appropriate approach. These inocula should first be tested in human volunteers in a step-wise manner to ensure safety, reproducibility, and curability prior to using them for testing the efficacy of candidate vaccines.

KW - Hepacivirus/genetics

KW - Hepatitis C

KW - Humans

KW - Reproducibility of Results

KW - treatment

KW - vaccine development

KW - acute hepatitis

KW - risk-benefit analysis

UR - https://www.scopus.com/pages/publications/85168210876

U2 - 10.1093/cid/ciad336

DO - 10.1093/cid/ciad336

M3 - Journal article

C2 - 37579208

SN - 1058-4838

VL - 77

SP - S257-S261

JO - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

IS - Suppl 3

ER -

Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this